Y-mAbs Therapeutics Inc (YMAB)
11.56
-0.29
(-2.45%)
USD |
NASDAQ |
May 17, 16:00
11.56
0.00 (0.00%)
After-Hours: 20:00
Y-mAbs Therapeutics Revenue (Quarterly): 19.93M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 19.93M |
| December 31, 2023 | 23.36M |
| September 30, 2023 | 20.45M |
| June 30, 2023 | 20.75M |
| March 31, 2023 | 20.25M |
| December 31, 2022 | 31.45M |
| September 30, 2022 | 12.54M |
| Date | Value |
|---|---|
| June 30, 2022 | 10.80M |
| March 31, 2022 | 10.49M |
| December 31, 2021 | 9.598M |
| September 30, 2021 | 8.965M |
| June 30, 2021 | 10.95M |
| March 31, 2021 | 5.383M |
| December 31, 2020 | 20.75M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.383M
Minimum
Mar 2021
31.45M
Maximum
Dec 2022
16.12M
Average
16.23M
Median
Revenue (Quarterly) Benchmarks
| The Cooper Companies Inc | 931.60M |
| Puma Biotechnology Inc | 43.77M |
| Humacyte Inc | -- |
| NovaBay Pharmaceuticals Inc | 2.631M |
| Palatin Technologies Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.629M |
| Total Expenses (Quarterly) | 26.84M |
| EPS Diluted (Quarterly) | -0.15 |
| Enterprise Value | 433.29M |
| Gross Profit Margin (Quarterly) | 89.23% |
| Profit Margin (Quarterly) | -33.26% |
| Earnings Yield | -4.22% |
| Normalized Earnings Yield | -4.224 |